Nothing Special   »   [go: up one dir, main page]

SG11202004187UA - Lyophilized formulation of a monoclonal antibody against transthyretin - Google Patents

Lyophilized formulation of a monoclonal antibody against transthyretin

Info

Publication number
SG11202004187UA
SG11202004187UA SG11202004187UA SG11202004187UA SG11202004187UA SG 11202004187U A SG11202004187U A SG 11202004187UA SG 11202004187U A SG11202004187U A SG 11202004187UA SG 11202004187U A SG11202004187U A SG 11202004187UA SG 11202004187U A SG11202004187U A SG 11202004187UA
Authority
SG
Singapore
Prior art keywords
monoclonal antibody
antibody against
lyophilized formulation
transthyretin
against transthyretin
Prior art date
Application number
SG11202004187UA
Inventor
Andrea Hawe
Ruedeeporn Tantipolphan
Jay Soto
Stefan Heindl
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of SG11202004187UA publication Critical patent/SG11202004187UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202004187UA 2017-11-29 2018-11-28 Lyophilized formulation of a monoclonal antibody against transthyretin SG11202004187UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592294P 2017-11-29 2017-11-29
PCT/US2018/062902 WO2019108689A1 (en) 2017-11-29 2018-11-28 Lyophilized formulation of a monoclonal antibody against transthyretin

Publications (1)

Publication Number Publication Date
SG11202004187UA true SG11202004187UA (en) 2020-06-29

Family

ID=66665773

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004187UA SG11202004187UA (en) 2017-11-29 2018-11-28 Lyophilized formulation of a monoclonal antibody against transthyretin

Country Status (18)

Country Link
US (1) US11873332B2 (en)
EP (1) EP3717512A4 (en)
JP (1) JP7337057B2 (en)
KR (1) KR20200090164A (en)
CN (1) CN111433223B (en)
AU (1) AU2018375356A1 (en)
BR (1) BR112020010483A2 (en)
CA (1) CA3083356A1 (en)
CL (1) CL2020001391A1 (en)
CU (1) CU20200042A7 (en)
EA (1) EA202091130A1 (en)
IL (1) IL274958A (en)
JO (1) JOP20200132A1 (en)
MA (1) MA51223A (en)
MX (1) MX2020005433A (en)
PE (1) PE20211453A1 (en)
SG (1) SG11202004187UA (en)
WO (1) WO2019108689A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
MX2020003041A (en) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anti-transthyretin antibodies.
MX2020005433A (en) 2017-11-29 2020-08-27 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin.
JP7266108B2 (en) 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー therapeutic antibody formulation
JP2023525790A (en) 2020-05-12 2023-06-19 ニューリミューン エイジー Combination therapy for TTR amyloidosis
JP2023548005A (en) * 2020-10-28 2023-11-15 ノヴォ ノルディスク アー/エス Anti-transthyretin antibody and its use
CN113845593B (en) * 2021-10-27 2023-03-10 福州迈新生物技术开发有限公司 anti-alpha-SMA protein monoclonal antibody, cell line and application thereof
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
WO2024105092A1 (en) 2022-11-15 2024-05-23 Neurimmune Ag Pharmaceutical compositions for treating or preventing transthyretin-mediated amyloidosis
WO2024105062A1 (en) 2022-11-15 2024-05-23 Neurimmune Ag Methods for treating or preventing transthyretin-mediated amyloidosis
WO2024123791A1 (en) * 2022-12-05 2024-06-13 Kodiak Sciences Inc. Formulations for dual vegf/il-6 inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1353944A2 (en) 2000-04-05 2003-10-22 The University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
WO2010012004A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
US20110200609A1 (en) 2002-09-12 2011-08-18 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence
WO2010011999A2 (en) 2008-07-25 2010-01-28 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
CA2498407A1 (en) 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
EP1660533A4 (en) 2003-09-12 2009-10-21 Univ California Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US8236933B2 (en) 2005-04-13 2012-08-07 Garvan Institute Of Medical Research Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor
JP5823663B2 (en) 2006-03-03 2015-11-25 プロミス ニューロサイエンシズ インコーポレイテッド Methods and compositions for treating and detecting misfolded SOD1-mediated diseases
WO2008005455A2 (en) 2006-07-03 2008-01-10 The Johns Hopkins University Peptide antibody depletion and its application to mass spectrometry sample preparation
EP2078189B1 (en) 2006-10-20 2012-10-10 Clondiag GmbH Assay devices and methods for the detection of analytes
WO2010030203A1 (en) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
DK2342220T3 (en) 2008-10-06 2021-08-09 Univ British Columbia METHODS AND SYSTEMS FOR PREDICTING MISFOLD PROTEIN PITOPES
JP2010195710A (en) 2009-02-25 2010-09-09 Kumamoto Univ Amyloid fibril formation inhibitor and use thereof
WO2010099612A1 (en) 2009-03-02 2010-09-10 The University Of British Columbia Antibodies and epitopes specific to misfolded prion protein
TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
FI20115165A0 (en) 2011-02-21 2011-02-21 Polysackaridforskning I Uppsala Ab Therapeutic and diagnostic methods
WO2012115241A1 (en) 2011-02-25 2012-08-30 中外製薬株式会社 Fcγriib-specific fc antibody
EP3825325A3 (en) 2011-03-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
TW201326209A (en) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
DK2857419T3 (en) 2012-05-30 2021-03-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for the elimination of aggregated antigens
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US9534048B2 (en) 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
UA118441C2 (en) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Antibodies recognizing alpha-synuclein
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
WO2014142334A1 (en) 2013-03-12 2014-09-18 国立大学法人名古屋大学 Method for increasing photosynthesis and yield of plants
WO2015010118A2 (en) 2013-07-19 2015-01-22 The University Of Texas Transthyretin amyloid-selective and polyreactive catabodies
KR102496162B1 (en) 2013-12-20 2023-02-09 뉴리뮨 홀딩 아게 Antibody-based therapy of transthyretin(ttr) amyloidosis and human-derived antibodies therefor
KR102240417B1 (en) 2014-01-29 2021-04-13 케이엠 바이올로직스 가부시키가이샤 Anti-transthyretin human antibody
JP6818268B2 (en) 2014-01-29 2021-01-20 Kmバイオロジクス株式会社 Anti-transthyretin humanized antibody
SI3185957T1 (en) 2014-08-29 2022-11-30 Alnylam Pharmaceuticals, Inc. Patisiran for use in treating transthyretin mediated amyloidosis
TWI705827B (en) * 2014-11-07 2020-10-01 瑞士商諾華公司 Methods for treating ocular diseases
TWI769570B (en) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI718122B (en) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI718121B (en) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
JP7076711B2 (en) 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド Anti-transthyretin antibody
JP7016470B2 (en) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド Anti-transthyretin antibody
JP7017013B2 (en) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド Anti-transthyretin antibody
CN107389956B (en) * 2017-08-31 2019-05-07 北京臻惠康生物科技有限公司 New application and its kit of the transthyretin as TBI patient injury's Severity
MX2020003041A (en) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anti-transthyretin antibodies.
JP7292569B2 (en) 2017-10-06 2023-06-19 ノボ ノルディスク エー/エス Methods for detecting transthyretin
MX2020005433A (en) 2017-11-29 2020-08-27 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin.
WO2021168156A1 (en) 2020-02-20 2021-08-26 Prothena Biosciences Limited Monitoring transthyretin amyloidosis

Also Published As

Publication number Publication date
KR20200090164A (en) 2020-07-28
PE20211453A1 (en) 2021-08-05
CN111433223B (en) 2024-08-27
CA3083356A1 (en) 2019-06-06
CU20200042A7 (en) 2021-03-11
EA202091130A1 (en) 2020-08-28
MX2020005433A (en) 2020-08-27
WO2019108689A1 (en) 2019-06-06
MA51223A (en) 2020-10-07
IL274958A (en) 2020-07-30
BR112020010483A2 (en) 2020-10-20
JP7337057B2 (en) 2023-09-01
AU2018375356A1 (en) 2020-05-14
JP2021504372A (en) 2021-02-15
CL2020001391A1 (en) 2020-11-13
EP3717512A1 (en) 2020-10-07
US11873332B2 (en) 2024-01-16
US20200362023A1 (en) 2020-11-19
CN111433223A (en) 2020-07-17
JOP20200132A1 (en) 2022-10-30
EP3717512A4 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
IL274958A (en) Lyophilized formulation of a monoclonal antibody against transthyretin
IL279321A (en) Anti-sirpα antibody
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
IL273411A (en) Anti-pd-l1 antibody and uses thereof
ZA202006797B (en) Anti-rsv monoclonal antibody formulation
EP3587453A4 (en) Anti-pd-l1 antibody and application thereof
EP3441086A4 (en) Anti-pd-1 monoclonal antibody
EP3532489A4 (en) Neutralizing anti-tl1a monoclonal antibodies
IL270698A (en) Canine antibody libraries
EP3480216A4 (en) Anti-pcsk9 monoclonal antibody
ZA202101177B (en) Anti-btla antibody
EP3103811A4 (en) Anti-tissue factor monoclonal antibody
EP3590964A4 (en) Improved anti-vegfr-2 monoclonal antibody
HK1246805A1 (en) Broad-spectrum monoclonal anti-flu b antibody and uses thereof
EP3567053A4 (en) Anti-claudin-2 monoclonal antibody
IL281717A (en) Antibody formulation
IL282813A (en) Antibody formulation
ZA202006263B (en) Antibody formulation
GB201811368D0 (en) Antibody
EP3432925A4 (en) Administration of an anti-lgr5 monoclonal antibody
GB201817172D0 (en) Antibody
EP3498838A4 (en) Anti-pd-l1 antibody
EP3365367A4 (en) Anti-bed bug monoclonal antibodies and methods of making and uses thereof
EP3404042A4 (en) Monoclonal antibody fnab8 and application thereof
HUE062818T2 (en) Ce-western applications for antibody development